---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-025099"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T22:58:30.740073+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Dr. Jerry Wang exits AnHeart Therapeutics CEO role after taletrectinib milestones achieved

## Summary
- Dr. Wang departed as CEO of AnHeart Therapeutics, a Nuvation Bio subsidiary, on Feb. 12, 2025.
- Departure follows China NMPA approval of taletrectinib for advanced ROS1-positive NSCLC.
- Also follows FDA acceptance and priority review of NDA for taletrectinib in advanced ROS1-positive NSCLC.
- Dr. Wang resigned from Nuvation Bio board effective Feb. 11, 2025; no disagreement with company.
- Role eliminated as redundant after successful integration of AnHeart Therapeutics post-merger.

## SEC filing metadata
- accession: 0001193125-25-025099
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312525025099/0001193125-25-025099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312525025099/d839065d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-025099
- JSON: https://secwatch.observer/filing/0001193125-25-025099.json
- Plain text: https://secwatch.observer/filing/0001193125-25-025099.txt

## Key facts
- Executive change
  Jerry Wang departed as Chief Executive Officer of AnHeart Therapeutics at Nuvation Bio Inc..
  - Action: departed
  - Role: Chief Executive Officer of AnHeart Therapeutics
  source text: On February 12, 2025, Dr. Jerry Wang, the Chief Executive Officer of AnHeart Therapeutics, a Nuvation Bio Inc. (the “Company”) company, departed the Company following the achievement of key Company goals
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811063/000119312525025099/0001193125-25-025099-index.htm
- Executive change
  Jerry Wang resigned as Member of the Board of Directors at Nuvation Bio Inc..
  - Action: resigned
  - Role: Member of the Board of Directors
  source text: Additionally, on February 11, 2025, Dr. Wang notified the board of directors (the “Board”) of his resignation as a member of the Board, effective February 11, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811063/000119312525025099/0001193125-25-025099-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.